Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.58 |
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.49 |
| ▸ | WNT3A | P56704 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582966 | 0.90 | MCHR1 (0.62) | MCHR1HTR2CTRPV1WNT3AROCK2 | |
| SCHEMBL5582742 | 0.89 | MCHR1 (0.57) | MCHR1HTR2CTRPV1 | |
| SCHEMBL5583001 | 0.85 | MCHR1 (0.60) | MCHR1HTR2CTRPV1WNT3A | |
| SCHEMBL5583074 | 0.82 | RAB9A (0.53) | MCHR1HTR2CTRPV1 | |
| SCHEMBL5582614 | 0.79 | MCHR1 (0.56) | MCHR1HTR2CTRPV1ROCK2 | |
| SCHEMBL5582951 | 0.78 | MCHR1 (0.63) | MCHR1HTR2CWNT3A | |
| SCHEMBL5582952 | 0.77 | MCHR1 (0.61) | MCHR1HTR2CWNT3A | |
| SCHEMBL2926448 | 0.76 | MCHR1 (0.81) | MCHR1HTR2CTRPV1WNT3A | |
| SCHEMBL5582521 | 0.75 | MCHR1 (0.64) | MCHR1HTR2CTRPV1WNT3A | |
| SCHEMBL7694273 | 0.75 | ROCK2 (0.43) | TRPV1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885HTR2C 195/4885TRPV1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.